What The Study Did: The SARS-CoV-2 BNT162b2 (Pfizer-BioNTech) vaccine appeared to be safe and achieve satisfactory serologic status in patients with cancer. While there was a lag in antibody production compared with the rate in the noncancer control group, seroconversion occurred in most patients after the second dose.
Authors: Irit Ben-Aharon, M.D., Ph.D., of the Rambam Health Care Campus in Haifa, Israel, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/
Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Media advisory: The full article is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https:/